MRC Technology Appoints General Counsel and Company Secretary
News Feb 04, 2015
MRC Technology (MRCT) has appointed Dr Edward Bliss in the new role of General Counsel and Company Secretary. Edward will join MRCT on 16 March from Shire Pharmaceuticals plc, where he is currently Legal Director.
Prior to that he was the General Counsel and Company Secretary at Ark Therapeutics Group plc and he joined Ark from private practice with the international life sciences law firm Covington and Burling LLP.
A solicitor, Edward also holds a degree in Physiology and PhD in Neuroscience and brings a wealth of experience to the role. His responsibilities will include licensing, governance, compliance, and in-house legal affairs.
Welcoming Edward, Dave Tapolczay, Chief Executive Officer, MRC Technology said: “Ed will be a great asset and we look forward to him joining. Licensing is a key part of our mission to drive scientific research to benefit patients. We have already negotiated over 400 commercial licences and Ed will continue to build on this success.”
Dr Edward Bliss said: “It is a tremendous privilege to be joining MRC Technology and I look forward to working with Dave Tapolczay and his team in their important goal of progressing the further development of innovative medical research.”
Stem Cells in Menstrual Blood Could Help Diagnose EndometriosisNews
The Feinstein Institute for Medical Research scientists announced an experimental, rapid and non-invasive way to diagnose endometriosis, which may lead to earlier and more effective treatments for this disorder that affects approximately 176 million women globally.READ MORE
SMi’s 5th Annual Molecular Diagnostics Conference 2018 Agenda ReleasedNews
SMi proudly presents its 5th annual conference on Molecular Diagnostics, taking place at the Holiday Inn Kensington Forum, London, UK on 9th and 10th July 2018, with a half-day post-conference workshops on 11th July 2018.READ MORE
Pap Test Fluids Used to Test for Endometrial & Ovarian CancersNews
Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers developed by researchers at the Johns Hopkins Kimmel Cancer Center.
Comments | 0 ADD COMMENT
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018